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The most common cause of vision impairment in children is amblyopia. It is defined as impaired visual acuity in one or
both eyes that is present with no demonstrable abnormality of the visual pathway and is not immediately resolved by
wearing glasses. After the World Health Organization (WHO) recognized COVID-19 as a global pandemic on March
11, 2020, widespread changes and restrictions to social and sanitary practices have presented significant issues in access
to eye care during the COVID-19 pandemic. A reduction of more than 80% in pediatric eye care volume up to its total
cessation has been observed in different departments. In this scenario, reduced or absent eyesight, due to delay in timely
treatment of amblyopic conditions, could create major, long-lasting effects on all aspects of life, including daily personal
activities, interacting with the community, school and work opportunities and the ability to access public services.
Processes coming out of lockdown should be gradually easing restrictions giving priority to ophthalmology and eye
care facilities so that amblyopia does not remain unattended and irreversible as in adults due to lack of timely treatments.
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• Amblyopia is the most common causes of vision
problems in children and it is estimated at 1–6% in
different areas.
• It develops during early childhood when the visual
system is vulnerable to changes in visual stimulation
and it remains as permanent visual defect into adult-
hood if left untreated.
What is new
• Due to the COVID-19 pandemic, a dramatic reduc-
tion in the access to pediatric-eye-care has been
observed.
• If not reversible, a delay in timely treatment of
amblyopic conditions could lead to an increase in
disability and unsustainable social costs for many
Governments.
After the World Health Organization (WHO) recognized
COVID-19 as a global pandemic onMarch 11, 2020, wide-
spread changes and restrictions to social and sanitary prac-
tices have presented significant issues in access to eye-care
during the COVID-19 pandemic.1 Several national
ophthalmology societies have sought to defer any treat-
ment other than urgent or emergency care to contain
human to human viral transmission.2–4 Thus, to deal with
rising cases of COVID-19, the outbreak practically
brought all clinical activity to a standstill for several-weeks
and an increasing need to prioritize access to eye care while
broadly maintaining SARS-CoV-2 infection control.5–8
This poses many risks, delays or suspends non-essential
outpatient visits and elective surgical procedures.9–13
Patient visits and encounters have significantly decreased
in many subspecialties, with a loss of more than 81% of
annual patient volume for a two-week period in March
and April 2020 compared to the corresponding period in
2019 in eye care.14–16 In our experience, during the first
COVID-19 lockdown a reduction of more than 80% in
pediatric eye care volume up to its total cessation has
been observed in many of our departments. If reconfirmed,
this reduction in volume in pediatric eye care is second
only to that experienced in cataract surgery volumes, as a
consequence of the need to prioritize emergency
treatment.2,15
To date, no clear European data is available yet on the
impact of COVID-19 on pediatric eye care in different
National Health Systems. Thus, it is of paramount import-
ance to assess the impact of lockdown on ophthalmological
care and its future adverse consequences in terms of
disability and access to vision-saving cures for many
pediatric patients. To address this challenge, we have
brought together EUROCOVCAT (European COVID-19
Cataract Group), a group of ophthalmic surgeons, specia-
lists including pediatric ophthalmologists and experts
from 12 European countries, to discuss how to resume
practicing ophthalmology in the safest and most efficient
manner, and reduce the risk of eye diseases such as ambly-
opia. The group is also creating awareness among national
governments to allow ophthalmology practices to remain
open during lockdown to minimize unnecessary sight-loss,
particularly in vulnerable children in visual development.
EUROCOVCAT has organized conferences and calls
sharing fruitful experiences and perspectives on the
current context. An in-depth analysis of the current situa-
tion in pediatric eye care has been merged with the
updated literature and available recommendations from
scientific ophthalmic societies and healthcare institutions.
Here we summarize some recommendations practical
hints and key steps for the reorganization of pediatric
care management and reorganization during the time of
COVID-19, merging the experiences of the European
COVID-19 Cataract Group (EUROCOVCAT) including
the most update published literature and guidelines.
Additionally, new perspective and solutions are provided
to the health providers to facilitate and coordinate their
cooperation with in- and out-patient clinics.
Bangerter has defined amblyopia as an under-
functioning caused by deprivation.17 Accordingly, one
eye remains impaired and sends altered signals to the
brain. So, the patient uses the ‘good eye’ or normal eye
for all activities. This affects depth perception or stereopsis
that require healthy functioning in both eyes. Amblyopia
presents low visual acuity without any apparent abnormal-
ity of the visual pathway in one or both eyes and cannot be
immediately resolved by wearing glasses.18 The term is
used most frequently to refer to the unilateral condition,
although amblyopia may be bilateral.18 Refractive correc-
tion cannot reverse and cure the disease in adults, as
after the age of about 10 years, it cannot be fully
reversed.19–21 Amblyopia is categorized into three types:
strabismus (squint), stimulus deprivation such as cataract
or ptosis, and anisometropia.18
Amblyopia develops rapidly during early childhood
(birth to 8–10 years of age) when there is inadequate
visual stimulation in one eye as optic signals do not prop-
erly reach the brain.22 It remains a reversible condition18
and varies in incidence based on regions and age groups.
In children, impaired vision from birth or in early child-
hood can have a negative effect on their growth and devel-
opment if left untreated or not treated in a timely manner.
Indeed, a low vision in childhood may lead to inadequate
emotional and social development of the child with
severe adverse long-term social, psychological, and finan-
cial consequences for the families.23–26 Indeed, untreated
amblyopia rarely gets resolved spontaneously.27 About
one-fourth of the population of people with amblyopia
have visual acuity in the affected eye worse than 20/
2 European Journal of Ophthalmology 0(0)
100.28 There is significant neural plasticity in the ambly-
opic brain beyond the critical period.25
Baseline and clinical factors such as the initial visual
acuity, type of amblyopia, treatment initiation age, the effi-
cacy of the treatment modality and patient’s compliance
are key factors affecting the outcome.18,29 Hence, appro-
priate timely treatment during the critical period mitigates
adverse outcomes later. Although many ophthalmological
treatments are elective with scheduled visits or surgeries
and may be postponed without any major impact on
public health, the pediatric treatments should not be post-
poned as prolonged vision loss during formative periods
is irreversible.
Amblyopia may remain asymptomatic and undetected
for years to the parents or the impacted child, because
they typically have good visual acuity in the normal eye.
Therefore, during the preschool period, many children
remain undiagnosed because their eyes appear normal initi-
ally until school admission.18 Accordingly, it is readily
predictable that any delay or suspension in essential pedia-
tric eye interventions or procedures may cause significant
and rapid vision impairment to irreversible vision loss in
younger generations.
Some authors have already highlighted the silent impact
of increasing usage of digital devices on children’s eye
health during the ongoing COVID-19 pandemic.30,31
Before the COVID-19 outbreak children were growing
up in a highly visually demanding world where electronic
devices, e-readers, tablets, video games, and the ubiquitous
mobile phone were exploited for entertainment and leisure.
Increased digital screen time, near homework, and limited
outdoor activities were found to be associated with the
onset and progression of myopia, and can potentially be
worsened during and beyond the COVID-19 pandemic
outbreak period.30,31 Additionally, the diffusion of e-learn-
ing has recently increased the use of electronic devices as
tools for long-term daily use, leading to an exponential
increase in digital eye strain (DES), making it an emerging
public health problem with a reported prevalence of more
than 50% among children in the COVID era.32
Jayadev et al. have reported that approximately 80% of
outpatient visits in the pediatric ophthalmology department
in March and April 2020 (at the start of the lockdown) were
for refractive errors, of which 79% were for myopia.33
Nowadays with no definitive end in sight for the pandemic,
we are potentially facing scenario of ‘quarantine myopia’
which is potentially explosive. There are predictions of a
worsening of the myopic epidemic worldwide and is esti-
mated that over 50% of the world’s population will have
myopia by 2050.34,35 Recently, a prospective study
designed to investigate the refractive changes and preva-
lence of myopia in school-aged children during the
COVID-19 home confinement in 123,535 children aged
6 to 13 years, has reported a significant myopic shift for
children aged 6 to 8 years of approximately −0.3 diopters
in China.30 These results are consistent with the data of
another large-scale intervention study with 12-month
follow-up on myopia development among 1,001,749
schoolchildren of 1305 elementary and high schools.
Here, myopia increased approximately 1.5 times from
−0.23 D during the pre-COVID-19 to −0.343 D during
the post-COVID-19 period.36 Moreover, even if data are
still controversial, besides myopic progression, accommo-
dative dysfunction in children may be also on the rise due
to digital device usage.37,38 Accommodation spasm and
sudden onset esotropia are important consequences.39
The former presents with an acute, rapid increase in
myopia and requires dynamic, cycloplegic retinoscopy,
and a comprehensive assessment of the binocular visual
field.33 Receded near the point of convergence, large
near exophoria, reduced near the point of accommodation,
and lag of accommodation greater than +1.25 diopter
sphere demand further assessment for non-strabismic bin-
ocular vision dysfunction.40 Vision therapy may play
also a significant role in managing these anomalies.
With this information in mind, and to avoid any increase
in the incidence of amblyopia, some authors have already
proposed evidence-based recommendations on how to
adequately evaluate children during the amblyopic period
while reducing COVID-19 transmission.41,42 We believe
that the following recommendations should always be
implemented in all cases of suspected pediatric amblyopia
or myopia (Figure 1):
• If the child has already been screened and a diagno-
sis of amblyopia has been made, the treatment
should be continued and the appointment to
monitor the ametropia may be postponed without
any additional risk;
• If the child has not been seen and a decreased visual
acuity or strabismus is suspected, he/she should be
seen to eliminate an organic cause or the risk of
amblyopia, especially if under six years of age;
• If strabismus has already been diagnosed, an alter-
nating or unilateral occlusion depending on the
case should be started and maintained according
the last ophthalmological consultation and until the
next one; this treatment renewing may be carried
out via telemedicine;43,44
In any case, all children should be seen urgently to elim-
inate an organic cause (e.g. retinoblastoma, tumors, con-
genital glaucoma, infection, traumatic lesion of ocular
adnexa.) if under two years of age or with an acute onset
of strabismus or recent nystagmus or suspicious/obvious
organic problem (leukocoria, buphthalmos, megalocornea,
tearing, photophobia, red and/or painful eye, or trauma).
So far, we have limited data to accurately predict the
future course of the COVID-19 pandemic. Even though
many governments have already started easing the
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current stringent lockdown measures, the current phase
may last several months. Additionally, the diffusion of vac-
cines could prove beneficial in conditioning the return to
normal life and provide effective responses to a potential
COVID-19 resurgence. If pediatric patients are not
treated in a timely manner, limited healthcare facilities
might be overburdened with large number of cases not
being attended currently due to lockdown and eye care
facilities being converted into corona wards/hospitals in
Europe.
In this scenario, reduced or absent eyesight caused by the
delay in timely treatment of amblyopic conditions could
create major and long-lasting effects on all aspects of life
and affects daily personal activities, such as interacting with
the community, school and work opportunities and the
ability to access public services. Amblyopia could prove
costly and serious in the long run if patients are not attended
immediately,18 especially in the vulnerable young age of up
to 8 years, when cortical and optical nerves connecting the
brain and abnormal eye develop completely. If not reversed,
the limited access to sight-saving cures for many pediatric
patients could lead to harmful consequences in terms of
even permanent disability in younger generations.
Therefore, achieving a delicate balance between infection
control and the supply of ophthalmology services to properly
diagnose and treat childhood amblyopia is strongly recom-
mended and suggested to avoid unsustainable social costs
for many health care systems. Processes coming out of lock-
down should be gradually easing restrictions on priority on
eye care facilities (hospital/clinics) so that amblyopia does
not remain unattended and irreversible as in adults due to
lack of timely treatments. Adult low vision leads to a costly
visual impairment reducing access to professional activity.
Additionally, as eye health care providers, we need to
promptly identify those children, if necessary, using telemedi-
cine, who are at a higher risk of DES and progression of
myopia to manage them appropriately. A public awareness
campaign to improve safety measures, enhance early detec-
tion of DES, and promote prevention and screening measures
in our young citizens is strongly needed. Presently, different
screening tools are employed to assess the visual status of
children. Vision screening for school-age children is import-
ant to detect uncorrected refractive errors.45,46 AWHO study
has recommended that the screening of children for refractive
errors should be integrated into school health programs and
could be carried out by government and non-governmental
organizations as well.47 Pediatric health care providers will
need to screen and treat children and counsel their parents
and/or other caregivers during well-child visits with an eye
care practitioner for these new or worsened environmental
threats. It is crucial to make teachers and parents aware that
these practices can help to check the growing ill-effects of
lockdown.33,48 Restriction of online classes with breaks in
between sessions, promoting (permitted) outdoor activities,
encouraging “family” time with non-gadget-based learning
and entertainment are some measures that can be adopted.
Favoring care to those of higher socioeconomic means,
those with better access to care, and perhaps even of different
race groups, is also a priority49 to make care more equitable.
In this scenario, telemedicine delivered both in an asyn-
chronous or synchronous manner, may be a new tool
able to deliver inpatient and outpatient pediatric care,
educate pediatricians and patients’ families, and conduct
medical research during the COVID-19 emergency.43,44,50
Indeed, with proper materials, technology, and staffing, tel-
emedicine can be rapidly implemented to provide
Figure 1. Flow-chart of amblyopia management.
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continued patient care during pandemic conditions.2 It can
also provide access to pediatric care to remote and under-
served populations, considering its costs and sustainability,
and the actual lack of technology infrastructure on a
national scale. Ophthalmology relies heavily on objective
assessments through examination techniques and investi-
gations. Some techniques lend themselves to widely avail-
able smartphone and web-based technologies. These
include visual acuity examinations, contrast testing, color
vision testing, optical axial length and gaze photography.
However, most of them are sophisticated examinations
that must rely on specialized equipment with trained per-
sonnel to obtain standardized images. Nowadays, a multi-
tude of smartphone extensions have been developed to
obtain retinal imaging and are being systematically evalu-
ated in some ocular diseases. However, for most of these
applications, parameters around safety, efficacy, cyberse-
curity, privacy, and interoperability still need to be care-
fully tested before their approval.50
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